These findings created a rationale for targeting of ICOS directly in the tumour, which was also supported by our prior data demonstrating that ICOSL-expressing cellular vaccine could potentiate the efficacy of CTLA-4 blockade21. The gene discussed is ICOS; the disease is neoplasm.